Kornimate/medical-research-clean huggingface dataset:
acetylcholinesterase inhibitor in anorexia nervosa: multicenter, double-blind, placebo-controlled trial

Conditions: Anorexia Nervosa Restricting Type

Summary: the goal of this clinical trial is to learn if the daily take of donepezil can treat adult patient suffering from anorexia nervosa. the main question it aims to answer is : do daily donepezil intake permit weight gain and reduction of food restriction rituals ? the treatment is a capsule comprising a drug limiting the degradation of a neurotransmitter called acetylcholine. this treatment has long been used to treat certain cognitive disorders. researchers will compare two drug dosage and a look-alike capsule that contains no drug to see if the dose has an impact on the effect. participants will take one capsule per day for three months will have regular hospital visits for cognitive and metabolic tests.


Eligibility criteria:
inclusion criteria: * female * presence of the 3 dsm-v criteria for anorexia nervosa * restrictive subtype of anorexia nervosa according to dsm-5 * body mass index between 15 and 18.5 kg/m² * aged 18 to 65 years * resting heart rate \&gt; or = 40 bpm * use of a highly effective contraceptive method * affiliation or entitlement to a health insurance scheme * prior free, informed, and written consent exclusion criteria: * presence of one or more somatic criteria for hospitalization according to french has 2010 guidelines * past diagnosis of anorexia nervosa with binge-eating/purging type * past diagnosis of bulimia nervosa * past diagnosis of binge-eating disorder * associated diagnosis of schizophrenia and/or persistent delusional disorder and/or bipolar disorder * history of asthma or obstructive bronchopulmonary disease * history of peptic ulcer disease or concurrent treatment with non-steroidal anti-inflammatory drugs * history of epileptic disorders * renal insufficiency (glomerular filtration rate less than 60 ml/min according to the mdrd formula) * hepatic insufficiency or transaminase levels greater than 5 times the normal upper limit * conductance disorder characterized by electrocardiogram * qtc according to bazett's formula greater than 480 ms on electrocardiogram * current or recent (within three weeks prior to inclusion) psychotropic treatment (including antidepressants, to avoid interaction/potentiation in this population) * treatment involving the following cytochromes: p450, p3a4, p2d6 * known hypersensitivity to donepezil hydrochloride, piperidine derivatives, or any excipients of the investigational drug * pregnant or breastfeeding woman * person under legal protection measures * person under guardianship measures

Keywords: anorexia nervosa eating disorders donepezil habits
implementation of a pharmacist-driven antipsychotic deprescribing initiative in the pace setting: a pilot study

Conditions: Behavioral and Psychiatric Symptoms of Dementia; Insomnia

Summary: the aim of this pilot study is to determine the feasibility of implementing an antipsychotic deprescribing initiative that is driven by pharmacists working collaboratively with the program of all-inclusive care for the elderly (pace) interdisciplinary team.

no individual antipsychotic has been approved by the u.s. food and drug administration (fda) for treating insomnia or behavioral and psychological symptoms of dementia (bpsd). despite these medications being associated with significant harms, a considerable portion of older adults are prescribed antipsychotics for treatment of insomnia or bpsd. the aim of this study is to determine the feasibility of a pharmacist-driven antipsychotic deprescribing initiative in a community-based practice setting known as program of all-inclusive care for the elderly (pace). our primary objective is to assess and describe the implementation process, including barriers and enablers to implementation. our secondary objectives are to quantify and describe changes in antipsychotic prescribing following implementation; evaluate and report on antipsychotic re-initiations or changes in dosing; and evaluate and report on adverse drug withdrawal events (adwes) following antipsychotic deprescribing.

Eligibility criteria:
inclusion criteria: * participant enrolled in a pace organization during the implementation time period; * pace organization contractually receiving pharmacy services from carekinesis during the implementation time period; and, * participant's prescriber determines that the participant could potentially benefit from deprescribing the antipsychotic. exclusion criteria: * a diagnosis of bipolar disorder, schizophrenia, schizo-affective disorder, acute delirium, tourette's syndrome, tic disorders, autism, intellectual disability, developmental delay, obsessive-compulsive disorder, alcoholism, cocaine abuse, parkinson's disease psychosis, or major depressive disorder for which the antipsychotic is specifically prescribed as adjunctive treatment; * participant's prescriber determines that the participant would likely not benefit or could be harmed from deprescribing the antipsychotic; and, * participant, or healthcare decision-maker on behalf of the participant (e.g., caregiver) refuses to participate in the deprescribing initiative.

Keywords: sleep antipsychotic bpsd deprescribing
platelet activation in chronic inflammatory skin diseases

Conditions: Urticaria; Atopic Dermatitis

Summary: platelets are blood cells that are important in coagulation of the blood. these cells have recently been shown to play a role in a number of other biologic processes, for example inflammation. in this study the investigators will determine the extent of platelet activation in people suffering from common chronic skin inflammation-urticaria and allergic dermatitis.


Eligibility criteria:
inclusion criteria: urticaria or atopic dermatitis - exclusion criteria:lack of informed consent -

Keywords: platelet activation
hidradenitis - an analysis of genetic traits and linkages in families

Conditions: Hidradenitis Suppurativa

Summary: the aim of this study is to find a genetic link or family trait connecting persons with hidradenitis suppurativa (hs) to each other. as a result, discover the cause and perhaps treatment for hidradenitis suppurativa (hs).

hidradenitis suppurativa (hs) is a chronic, debilitating skin disease characterized by multiple abscesses located predominantly in areas such as armpit, genital, pelvic, and perineum. it is considered an orphan disease of unknown origin and no existing treatment with a population prevalence estimated between 1-4%. it develops in otherwise healthy patients after puberty and affects patients life-long. hs often requires multiple surgical procedures to drain large abscesses, or hospitalization to treat infected wounds, can lead to feelings of personal embarrassment and social stigmatization. anecdotal evidence from affected families shows that hs often "runs in families" and may be inherited in a mendelian fashion; however, no adequately powered study has been undertaken to investigate this hypothesis. this project aims to characterize the inheritance pattern of hs in families, and identify the genetic cause of this disease in those families with evidence for monogenic inheritance. data collection includes blood sample analysis (dna), medical history, and information pertaining to any known family history of hs, from which a familial pedigree can be generated. this 'family-based' genetic study design will include both affected and unaffected family members, ideally spanning several generations. therefore, study patients will be asked to refer their immediate and extended (affected and unaffected) family members to this research study.

Eligibility criteria:
inclusion criteria: * participants (affected) with hidradenitis suppurativa and related symptoms * family (unaffected) of participants with hidradenitis suppurativa exclusion criteria: * children under 7-years of age

Keywords: hidradenitis suppurativa hs acne inversa abscess boils
a study comparing the efficacy of ta103 and the placebo control in the treatment of interdigital tinea pedis.

Conditions: Tinea Pedis

Summary: to evaluate and compare the safety and efficacy of ta103 in the treatment of tinea pedis.

a multi-center, double-blind, randomized, placebo controlled, parallel-group study, comparing ta103 and the placebo control in the treatment of tinea pedis.

Eligibility criteria:
inclusion criteria: * healthy male or non pregnant female aged ≥ 18 years * subjects must have provided irb approved written informed consent * subjects must have clinical diagnosis of interdigital tinea pedis with lesions localized to the interdigital spaces or predominantly interdigital, but may extend to other areas of the foot (the non-interdigital lesions should not be hyperkeratotic, i.e., characteristic of tinea pedis moccasin). exclusion criteria: * female subjects who are pregnant, nursing or planning to become pregnant during study participation. * subjects with a history of hypersensitivity or allergy to any of the study medication ingredients and its excipients. * confluent, diffuse moccasin-type tinea pedis of the entire plantar surface.
feasibility study of tumor blood flow measurement by detection of positron activation post proton therapy (ds01)

Conditions: Brain Cancer; Prostate Cancer; Lung Cancer

Summary: the purpose of this study is the development of noninvasive (having no direct contact) detector and electronic system that will directly measure tumor blood flow rate.


Eligibility criteria:
inclusion criteria: solid tumors in the intracranial, thoracic, or pelvic regions. exclusion criteria: n/a -

Keywords: proton radiation tumor blood flow
effectiveness of invasive electrostimulation combined with an exercise program in plantar fasciitis

Conditions: Fasciitis, Plantar

Summary: this study evaluates the effectiveness of an electrostimulation treatment with tens using a needle and a surface electrode combined with an exercise program to fasciitis plantar. half participants will receive invasive electrostimulation (tens using a needle) and exercises while the other half will receive electrostimulation placebo and exercises.

there are a lot of treatments to fasciitis plantar. exercises are the treatments more recommended to fasciitis plantar but not all patients improve only with exercises. dry needling is recommended to relieve the pain in the heel. tens is used to decrease the pain in the fasciitis plantar. investigators will apply to half participants a treatment that combines tens + dry needling (invasive electrostimulation ) with exercises while the other half receive electrostimulation placebo (tens using surface electrodes with non-therapeutic intensity) + exercises.

Eligibility criteria:
inclusion criteria: * medical diagnosis of plantar fasciitis * age equal or superior to 18 years old. * vas minimum of 2 points int the first steps after a prolonged decreasing period. * having an evolution of a month or more of pain. * not having received acupuncture or dry needling as treatment. exclusion criteria: * peripheral neuropathies. * tarsus tunnel syndrome. * rheumatic diseases. * contraindication to dry needling: nickel allergy, fear of needles, sky with erosions. * clotting disorders such as thrombosis or thrombophlebitis. * fractures, infections and/ or tumor processes. * have been treated for plantar fasciitis in the las 4 weeks. * previous surgery in the foot * pregnancy. * communication disorders. * holders of pacemakers or electrostimulators.

Keywords: electrostimulation exercise program
step and walking pattern from cardiac monitor study

Conditions: Heart Failure NYHA Class II; Heart Failure NYHA Class III; Insertable Cardiac Monitor

Summary: to understand the feasibility of characterizing walking patterns in heart failure subjects and subjects at risk for arrhythmias using an investigational wearable monitor called the swan study system.

this is a non-randomized, feasibility study that will enroll up to 60 participants diagnosed with class ii (30-35%) or iii (30-35%) heart failure or are indicated for an insertable cardiac monitor with no history of heart failure (30-35%). there will be one study visit per participant and a follow up phone call. the study visit includes device placement and data collection during rest and during a 6 minute hall walk. the device will then be removed.

Eligibility criteria:
inclusion criteria: * subject is 18 years or older * willing and capable to provide written informed consent and agrees to participate in all protocol required activities * subjects must meet one of the following criteria: * documented new york heart association (nyha) class ii or iii heart failure within the last 6 months or * subjects that have a known heart condition (non-heart failure) and are at risk of developing an abnormal heart rhythm, or have symptoms that may suggest a cardiac arrhythmia such as dizziness, palpitations, syncope, chest pain and/or shortness of breath exclusion criteria: * not able to walk continuously for a period of 6 minutes at the subjects baseline walking speed * prior hospitalization or surgery that affects the subjects baseline walking speed at time of enrollment * cardiovascular event such as unstable angina or myocardial infarction that affects the subjects baseline walking speed at time of enrollment * subject is currently enrolled in another clinical trial (excluding registries) that may interfere with the placement of the study system * known allergy to materials used in the study (adhesive tape, titanium, ecg electrodes) * subject is pregnant as indicated by subject report and/or medical record at the time of enrollment * subjects with rash or open wound on torso locations where investigational devices will be placed * have an active implantable device * any past or current medical event that could represent a risk for the subject to perform the study required activities in the opinion of the investigator * any medical signs or symptoms that in the opinion of the investigator could represent a risk for the subject (i.e. increased baseline blood pressure or heart rate).

Keywords: exercise walk
the effect of brushing with salvadorapersica (miswak) sticks on salivary streptococcus mutants and plaque level in children: a clinical trial

Conditions: Plaque, Dental

Summary: objectives: to evaluate the effect of brushing with salvadora persica (miswak) on streptococcus mutants compared to brushing with fluoridated tooth paste (ftp) in children. methods: a total of 94 healthy children (8 years old) from an elementary governmental school in jeddah, saudi arabia were grouped to miswak and ftp groups. they were assessed for their salivary level of mutans streptococci species, and lactobacillus at the baseline and three weeks after brushing. caries level using dmft/dmft, and plaque amount using greene vermillion simplified oral hygiene index were recorded.


Eligibility criteria:
inclusion criteria: * healthy children * age from 8 to 9 * parents signed the consent form they attended morning session for brushing exclusion criteria: * medical compromised children * parents did not sign the consent form did not attend morning session
maximal strength training in patients undergoing total hip arthroplasty

Conditions: Muscle Weakness

Summary: conventional rehabilitation after total hip arthroplasty (tha) does not seem to restore muscular strength or walking speed. three-5 years after surgery patients are still not fully rehabilitated. this study evaluates the effects of maximal strength training on the muscular strength in leg press and abduction in patients undergoing tha. aim of the study is to increase the patients physical function through evidence-based rehabilitation in clinical practice, with gradually less supervision.


Eligibility criteria:
inclusion criteria: * scheduled for total hip arthroplasty (tha) * living nearby trondheim * diagnosis of primary osteoarthritis as the main cause for elective tha * asa score of i-iii (stable) exclusion criteria: * muscular or skeletal disease which might influence the training and/or physical testing performance * communication difficulties * postoperatively discharged to a rehabilitation institution * tha in the bilateral hip that is not fully rehabilitated.

Keywords: resistance training arthroplasty, replacement, hip professional-patient relations evidence-based practice
colesevelam versus placebo in cholestatic pruritus

Conditions: Chronic Liver Disease

Summary: 38 patients with pruritus due to chronic cholestatic liver disease will be evaluated in an investigator initiated, multicenter, double-blind, placebo-controlled, 3-week study assessing the effects of colesevelam on pruritus. colesevelam is an oral, non-absorbable bile-acid sequestrant much more potent than cholestyramine but free of adverse effects. it is registered as a lipid lowering agent. the intensity of symptoms will be scored by means of daily visual analogue scales (vas). fatigue, quality of life and cutaneous scratch lesions will also be evaluated using quantitative instruments.


Eligibility criteria:
inclusion criteria: * patients with pruritus as a result of a cholestatic disorder * age above 18 years * informed consent exclusion criteria: * use of cholestyramine * pregnancy * inability to understand or speak dutch language * malignancy/life expectancy \<6 months

Keywords: cholestatic pruritus of any cause
liver safety under upfront arimidex vs tamoxifen

Conditions: Breast Cancer

Summary: the primary objective is to compare arimidex (anastrozole) 1 mg once daily with tamoxifen 20 mg once daily as adjuvant treatment in terms of: incidence of fatty liver diseases. the second objectives are to compare arimidex (anastrozole) 1 mg once daily with tamoxifen 20 mg once daily as adjuvant treatment in terms of: incidences of abnormal liver function test, and time to treatment failure.


Eligibility criteria:
inclusion criteria: * histologically proven hr+ invasive breast cancer * completed all primary surgery and chemotherapy (if given), and were candidates to receive hormonal adjuvant therapy * postmenopausal woman exclusion criteria: * clinical evidence of metastatic disease * previous adjuvant hormonal therapy for breast cancer * liver diseases

Keywords: early breast cancer adjuvant therapy hormone receptor hormonal therapy anastrozole tamoxifen
new prognostic predictive models of mortality of decompensated cirrhotic patients waiting for liver transplantation

Conditions: Decompensated Cirrhosis; Liver Transplantation

Summary: the meld score is a predictive model of cirrhosis mortality used in france since 2007 to prioritize access to liver transplantation for patients enrolled in the national waiting list. the predictive value of this score was recently revised downward with a c index of the order of 0.65-0.67 and 20% of the patients enrolled for decompensated cirrhosis have access to liver transplantation by a subjective system of "expert component" independent of the meld because of this lack of precision. the use of the meld score to individually define access to the transplant should so be reconsidered. recently new predictive models of cirrhosis mortality better than meld have been developed and new mortality predictors independent of meld have been published. the goal of this study is to design prognostic predictive models of mortality for decompensated cirrhotic patients enrolled on the national liver transplant waiting list including known (meld, meld na) as more recent (clif-c ad, clif - caclf) predictive models and new objective predictors studied in combination in order to optimize the system of allocation of hepatic allografts in france. the expected benefits of this search are twofold: * at the individual level: the possibility for patients at high risk of death but with intermediate meld score to be transplanted. * public health plan: * improving the equity of graft allocation system. * decreased mortality in the waiting list by improving the fairness and efficiency of the graft allocation system, a major public health issue


Eligibility criteria:
inclusion criteria: * adult patients (≥18 years old) newly registered on national waiting list with main diagnosis "cirrhosis" * patients enrolled on the national waiting list under the "national liver score" allocation scheme whether an expert component is considered or not * patients (or trusted person or family member or close relation if the patient is unable to express consent) who have been informed and signed their informed consent * patients affiliated to a health insurance scheme exclusion criteria: * patients enrolled with decompensated cirrhosis associated with hepatocellular carcinoma * patients on avk (inr and therefore meld and clif scores uninterpretable) * vulnerable population (person under guardianship or curatorship or deprived of liberty by a judicial decision) * pregnant and / or breastfeeding woman

Keywords: liver transplantation predictive prognostic models decompensated cirrhosis
after hip fracture nailing, compare early weight bearing as tolerated (wbat) group with weight bearing restriction(wbr)

Conditions: Bony Weight Bearing Disorder

Summary: purpose: proximal femur fracture is a major traumatic injury in elderly populations; however, practical postoperative weight-bearing protocols are lacking. therefore, the purpose of the present study was to investigate whether early weight-bearing status after proximal femur nail fixation is associated with any loss of reduction and evaluate the clinical outcomes of this intervention. patients and methods: for this prospective single-center clinical trial study, we recruited 60 geriatric proximal femur fracture cases, classified by ao/ota 2018, receiving intramedullary nail fixation. the participants were assigned to the early-weight-bearing group (n= 30) or the weight-bearing restriction group (n = 30). clinical outcomes included the harris functional hip score and vas pain score. additionally, demographic data, radiological parameters, time to weight-bearing, mortality rate, medical and surgical complications, and final ambulation status were recorded.


Eligibility criteria:
inclusion criteria: * patients with ao/ota type 31 fractures were included, and all fractures were classified using intraoperative fluoroscopy with traction on the fracture table. exclusion criteria: * patients with pathological fractures, neurovascular insufficiency, ipsilateral lower extremity musculoskeletal injury, multiple fractures, or high risk of falling, including frequent falling accidents within 6 months, unsteady gait, ipsilateral neuropathy, limb weakness, and urinary incontinence were excluded.

Keywords: fracture reduction proximal femur fracture geriatrics early weight-bearing